MS - Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting | Benzinga
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement Service (‘PCRS’) has approved Althea THC20:CBD1 cannabis oil for reimbursement in Ireland. The company’s subsidiary, MyAccess Clinics, a private medical clinic specializing in medicinal cannabis, will offer consultations to patients in Ireland beginning in November.
The news comes on the heels of Ireland’s Citizens Assembly on Drugs Use voting in favor of a new health-led approach to drugs and illegal substances.
Althea THC20:CBD1 has now been added to the PCRS in Ireland, making it free of charge for Irish patients being treated for intractable nausea and vomiting associated with chemotherapy (CINV). The agreed reimbursement price for the company’s marijuana oil is €330 ($350).
"The addition of Althea THC20:CBD1 to the Primary Care Reimbursement Service in Ireland is another remarkable achievement for Althea and solidifies our position as the global leader in the sale and distribution of medicinal cannabis extracts,” stated Joshua Fegan CEO of AGH. "MyAccess Clinics has already serviced thousands of patients in the UK, and we look forward to offering an ...